Right-To-Try or Right To Ask?

This white paper is part of DIA’s White Paper Library

Programs providing seriously ill patients with early access to investigational products are of great interest to the public, but what are the implications to pharmaceutical and biotechnology product companies? This article examines Right-to-Try legislation as well as FDA’s existing expanded access programs from the perspective of companies who are considering providing investigational products to patients with serious or life threatening diseases that have exhausted all other treatment options.

Download Now!
INTERESTED IN PUBLISHING?

For more information on publishing your White Paper with DIA, including schedule and pricing, please contact Heej Ko at Heej.Ko@DIAglobal.org.